Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 89, Issue 9, Pages 915-925
Publisher
Wiley
Online
2014-08-14
DOI
10.1002/ajh.23703
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review
- (2014) Mrinal M. Patnaik et al. BRITISH JOURNAL OF HAEMATOLOGY
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
- (2014) P Guglielmelli et al. LEUKEMIA
- An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
- (2014) A Tefferi et al. LEUKEMIA
- CALR mutations and a new diagnostic algorithm for MPN
- (2014) Ayalew Tefferi et al. Nature Reviews Clinical Oncology
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype
- (2013) A Tefferi et al. LEUKEMIA
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
- (2012) T. L. Lasho et al. BLOOD
- Polyclonal Immunoglobulin Free Light Chain Levels Predict Survival in Myeloid Neoplasms
- (2012) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms
- (2012) Ayalew Tefferi NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
- (2011) A. Tefferi et al. BLOOD
- Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis
- (2011) H. J. Deeg et al. BLOOD
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- EZH2 mutational status predicts poor survival in myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients
- (2011) A Pardanani et al. LEUKEMIA
- IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
- (2011) A Tefferi et al. LEUKEMIA
- SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients
- (2011) T L Lasho et al. LEUKEMIA
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
- (2011) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy
- (2010) Michelle A. Neben-Wittich et al. AMERICAN JOURNAL OF HEMATOLOGY
- Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
- (2010) Alejandra Martínez-Trillos et al. ANNALS OF HEMATOLOGY
- Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
- (2010) F. Passamonti et al. BLOOD
- Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt
- (2010) Elena Mishchenko et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
- (2010) C. Elena et al. HAEMATOLOGICA
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase-2 trial of low-dose pomalidomide in myelofibrosis
- (2010) K H Begna et al. LEUKEMIA
- Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
- (2010) D Caramazza et al. LEUKEMIA
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
- (2010) A Tefferi LEUKEMIA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome of Transplantation for Myelofibrosis
- (2009) Karen K. Ballen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
- (2009) K. Hussein et al. BLOOD
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
- (2009) P. Guglielmelli et al. BLOOD
- Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2009) N. Kroger et al. BLOOD
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level
- (2009) Jocelin Huang et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Conventional cytogenetics in myelofibrosis: literature review and discussion
- (2009) Kebede Hussein et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival
- (2009) Mrinal M. Patnaik et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
- (2009) Constantine S. Tam et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
- (2009) A Tefferi et al. LEUKEMIA
- TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
- (2009) A Tefferi et al. LEUKEMIA
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
- Refining the Selection Criteria for Laparoscopic Versus Open Splenectomy for Splenomegaly
- (2008) Liane S. Feldman et al. Journal of Laparoendoscopic & Advanced Surgical Techniques
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now